In line with this previous study, our PDX models showed high sensitivity to dasatinib ex vivo in the absence of LCK or SRC mutations (Supplementary Data 1), underscoring the potential use of this drug for T-ALL treatment. Here, SRC is linked to acute lymphoblastic leukemia.